Breo Ellipta 100 ug/1

Breo Ellipta 100 ug/1 is a combination inhaler containing fluticasone furoate and vilanterol trifenatate. It is designed for respiratory use to help manage symptoms of certain lung conditions. This powder inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Breo Ellipta 100 ug/1 is commonly used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. The inhaler combines a corticosteroid and a long-acting beta-agonist to reduce inflammation and relax the muscles in the airways, making it easier to breathe. It is often prescribed for individuals who require both types of medication to manage their respiratory symptoms effectively.

When used as directed, Breo Ellipta 100 ug/1 may help improve lung function and reduce symptoms such as wheezing, shortness of breath, and coughing. Some users may experience common effects like headache, throat irritation, or a dry mouth. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider.

Breo Ellipta 100 ug/1 should be used with caution, especially by individuals with a history of heart conditions, high blood pressure, or thyroid problems. It is important to follow the prescribed dosage and administration instructions carefully. The inhaler should be stored at room temperature and kept away from moisture and heat. Always inform your healthcare provider about any other medications you are taking to avoid potential interactions.

Breo Ellipta 100 ug/1 may interact with certain medications, including other respiratory drugs, beta-blockers, and some antidepressants. It is important to avoid using this inhaler with other long-acting beta-agonists unless directed by a healthcare provider. Additionally, consuming alcohol while using this medication may increase the risk of side effects. Always consult a healthcare provider before starting any new medication.